237 related articles for article (PubMed ID: 24563373)
1. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.
Mokuyasu S; Suzuki Y; Kawahara E; Seto T; Tokuda Y
Breast Cancer; 2015 Nov; 22(6):563-9. PubMed ID: 24563373
[TBL] [Abstract][Full Text] [Related]
2. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
3. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
[TBL] [Abstract][Full Text] [Related]
5. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
7. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
8. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
Cadeddu C; Piras A; Dessì M; Madeddu C; Mantovani G; Scartozzi M; Hagendorff A; Colonna P; Mercuro G
Int J Cardiovasc Imaging; 2017 Feb; 33(2):197-207. PubMed ID: 27696298
[TBL] [Abstract][Full Text] [Related]
9. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
10. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
12. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E
Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043
[TBL] [Abstract][Full Text] [Related]
13. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
[TBL] [Abstract][Full Text] [Related]
14. Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
Altundag K
Breast Cancer; 2017 Nov; 24(6):794. PubMed ID: 28275991
[No Abstract] [Full Text] [Related]
15. Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i.
Lippi G; Pighi L; Paviati E; Demonte D; De Nitto S; Gelati M; Montagnana M; Gandini G; Henry BM; Salvagno GL
Clin Chem Lab Med; 2024 Jun; 62(7):1433-1437. PubMed ID: 38176023
[TBL] [Abstract][Full Text] [Related]
16. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
[TBL] [Abstract][Full Text] [Related]
19. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
Ky B; Putt M; Sawaya H; French B; Januzzi JL; Sebag IA; Plana JC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Coll Cardiol; 2014 Mar; 63(8):809-16. PubMed ID: 24291281
[TBL] [Abstract][Full Text] [Related]
20. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay.
Krintus M; Kozinski M; Boudry P; Capell NE; Köller U; Lackner K; Lefèvre G; Lennartz L; Lotz J; Herranz AM; Nybo M; Plebani M; Sandberg MB; Schratzberger W; Shih J; Skadberg Ø; Chargui AT; Zaninotto M; Sypniewska G
Clin Chem Lab Med; 2014 Nov; 52(11):1657-65. PubMed ID: 24897400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
